Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.
about
Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the hostStructure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant EpitopeThe Complexity of a Dengue Vaccine: A Review of the Human Antibody ResponseDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityA potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surfaceMapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to DENV4 Infection and VaccinationProtective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus InfectionA single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesisDengue serotype cross-reactive, anti-e protein antibodies confound specific immune memory for 1 year after infection.Utility, limitations, and future of non-human primates for dengue research and vaccine developmentThe potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope proteinDissection of antibody specificities induced by yellow fever vaccinationIdentification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibodyThe type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteinsDengue vascular leakage is augmented by mast cell degranulation mediated by immunoglobulin Fcγ receptors.The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2.Comprehensive mapping infection-enhancing epitopes of dengue pr protein using polyclonal antibody against prMIdentification of human neutralizing antibodies that bind to complex epitopes on dengue virionsA new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus.Sculpting humoral immunity through dengue vaccination to enhance protective immunityTherapeutic antibodies as a treatment option for dengue fever.A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from diseaseBroad and strong: the ultimate antibody to dengue virus.Functional analysis of dengue virus (DENV) type 2 envelope protein domain 3 type-specific and DENV complex-reactive critical epitope residues.Evaluation in mice of the immunogenicity and protective efficacy of a tetravalent subunit vaccine candidate against dengue virus.Barriers to preclinical investigations of anti-dengue immunity and dengue pathogenesis.
P2860
Q23925011-937EC8C7-F2CD-4F66-8A36-E346345279FBQ26700120-725BD59D-10F4-40AF-85A5-4C29D8AFD439Q26995782-3D7CB68A-B55F-49AC-8026-939A893998D4Q27654848-4BD5720C-C650-4042-973B-C6C213E43096Q27681319-14B80A22-DF49-40E4-8874-266F7D9E070FQ28114614-86AD0FA9-8945-4A27-B6A8-3669F13587E7Q28119679-FA04161B-4825-4CD7-AF53-3A3865BFA984Q28804076-984626BD-16C8-4156-B54E-AE62B4CC786EQ34042859-0554B14C-8D2A-4D25-8153-598D2364BAC4Q34238916-AA219313-4818-49BE-8E69-BC506407BCC9Q34386384-4031944F-B6F9-4383-B21D-93F863FB399CQ34789343-130FFCCF-60C2-463F-BDAB-C0EA62920F5DQ34976206-12024F44-2F03-49F6-80A7-C50C5ADCAA27Q35069160-CD23446A-24C3-408A-BA05-5C8E1B07EFD6Q35138111-287BA0AC-E328-449D-846F-8DADEFABFF37Q35183803-F0AA5B03-76BA-40BD-81AB-BC5E6168EF19Q35236379-BE932A1D-E66E-491A-AF49-DDE92704FE6BQ35781863-7B080277-B911-4EA9-8996-EEA076E5CA39Q35982791-CACB1C33-F5F8-4BF0-A7D5-04E96C965AA7Q36205859-1D9EF0BF-13E5-475D-868B-4FB4ABF904A4Q36234359-137EFEBB-97C9-4A41-BD85-A8C88BE1F62BQ36286276-E9BDE8C2-8035-4EE8-B66D-2BED39321AB5Q36382589-52CCC2AF-294E-4210-BDC8-0F6151D8B726Q38149195-69A388E2-5C56-4D03-8531-06955FCF5035Q39811978-539E4758-C13B-401F-AC4D-31A44F57AD07Q40173610-49AABE76-02CE-44D5-992F-EB77DEAF4032Q40185205-D1CEB8F7-F49E-414F-B439-A1E97F35DE1EQ40212190-6B2CE986-56F6-4199-9757-FCF4E4F5DBAFQ42991886-CE17F0A8-54A5-417C-8885-A4A840EFBA8A
P2860
Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Recombinant dengue type 2 viru ...... tralized by human immune sera.
@en
type
label
Recombinant dengue type 2 viru ...... tralized by human immune sera.
@en
prefLabel
Recombinant dengue type 2 viru ...... tralized by human immune sera.
@en
P2093
P2860
P356
P1433
P1476
Recombinant dengue type 2 viru ...... tralized by human immune sera.
@en
P2093
Claire Huang
Laura J White
Siritorn Butrapet
Wahala M P B Wahala
P2860
P304
P356
10.1128/JVI.06871-11
P407
P577
2012-01-25T00:00:00Z